Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | LIG1 | P18858 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125735 | 0.87 | TDP1 (0.56) | MAPTNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL6121031 | 0.81 | FLT3 (0.47) | MAPTNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL2187527 | 0.79 | ALDH1A1 (0.50) | NPC1RAB9ASMN1; SMN2FLT3LIG1 | |
| SCHEMBL3955768 | 0.79 | FLT3 (0.66) | MAPTNPC1RAB9APOLBFLT3 | |
| SCHEMBL11821446 | 0.79 | GAA (0.62) | MAPTNPC1RAB9APOLBFLT3 | |
| SCHEMBL4126877 | 0.79 | FLT3 (0.46) | MAPTPOLBSMN1; SMN2FLT3LIG1 | |
| SCHEMBL10739254 | 0.78 | TDP1 (0.54) | MAPTNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL13596056 | 0.77 | FLT3 (0.47) | MAPTNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL7326428 | 0.77 | TDP1 (0.71) | MAPTNPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL1938254 | 0.75 | ALDH1A1 (0.64) | NPC1FLT3KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | MAPT 4157/4885NPC1 643/4885RAB9A 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.